Zobrazeno 1 - 10
of 207
pro vyhledávání: '"T, Horimi"'
Autor:
Y. Fukuda, K. Uchida, Norio Yoshimura, T. Nakatani, Hidetaka Ushigome, Kenji Yuzawa, S. Ito, T. Horimi, Masato Fujisawa, Kiyokazu Akioka, A. Sugitani, Kazuo Nishimura
Publikováno v:
Transplantation proceedings. 48(3)
Mizoribine (MZR) is an immunosuppressive agent that exhibits a less potent immunosuppressive effect at doses up to 3 mg/kg/d. We investigated whether high-dose MZR is effective and safe for renal transplant patients in conjunction with cyclosporine (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66f15ae541e572439e8c0d7664412924
https://pubmed.ncbi.nlm.nih.gov/27234738
https://pubmed.ncbi.nlm.nih.gov/27234738
Autor:
A. Sugitani, Kiyokazu Akioka, S. Ito, Norio Yoshimura, Y. Ichikawa, Kenji Yuzawa, Masato Fujisawa, Y. Fukuda, T. Horimi, K. Uchida, K. Nishimura, T. Nakatani
Publikováno v:
Transplantation Proceedings. 44:147-149
We performed a multicenter study in Japan to assess the efficacy and safety of immunosuppressive therapy with high-dose mizoribine (MZR; 6 mg/kg) combined with basiliximab (Bas), cyclosporine (CyA), and a corticosteroid in 90 patients. MZR was adjust
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffbb2acf3c64d999d44ffcf0ac8d57c8
https://doi.org/10.1016/j.transproceed.2011.11.015
https://doi.org/10.1016/j.transproceed.2011.11.015
Autor:
S Nakatani, Hiromi Iwagaki, Hiroshi Isozaki, Nagahide Matsubara, Noriaki Tanaka, Norihisa Takakura, T Horimi, Takahiro Okabayashi
Publikováno v:
Journal of International Medical Research. 27:27-37
Streptococcal preparation OK-432 is a bacterial immunopotentiator extensively used in Japan for adjuvant cancer therapy. Using C3H/He mice bearing MH-134 tumour cells, cytokine inductions of tumour necrosis factor-alpha, interleukin 1 beta, interleuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fcfe14833f5f1ec8d43e4b178c546b5
https://doi.org/10.1177/030006059902700104
https://doi.org/10.1177/030006059902700104
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 27
We evaluate the efficacy and toxicities of low-dose FP therapy in the treatment of advanced and recurrent gastric and colorectal adenocarcinomas. 104 patients (gastric adenocarcinoma: 52, colorectal adenocarcinoma: 52) were enrolled. Low-dose FP ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4221613c1a34ce8e77b1e129613d8c20
https://pubmed.ncbi.nlm.nih.gov/10895205
https://pubmed.ncbi.nlm.nih.gov/10895205
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 27(2)
5-fluorouracil (5-FU) has been widely used for the treatment of gastrointestinal cancers. Low-dose cisplatin (CDDP) and continuous venous infusion of 5-FU have recently shown additive or synergistic antitumor effects in experimental models. In this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::abbd9f413ebc657519200f1ec478892b
https://pubmed.ncbi.nlm.nih.gov/10700893
https://pubmed.ncbi.nlm.nih.gov/10700893
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 26
Shortening the period of hospitalizations and improving QOL attracting a great deal of attention in the field of medicine recently. Therefore, ambulatory and domiciliary treatment has become more important. This is not an exception in cancer therapy;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::84cbe5d9c74e1959032485bab49ba031
https://pubmed.ncbi.nlm.nih.gov/10630242
https://pubmed.ncbi.nlm.nih.gov/10630242
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 26(7)
5-fluorouracil (5-FU) has been widely used for the treatment of gastrointestinal cancers. On the basis of recent findings, low-dose Cisplatin (CDDP) and continuous venous infusion of 5-FU have shown additive or synergistic antitumor effects in experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::68e2193c53e38937c53c5a8173c9e678
https://pubmed.ncbi.nlm.nih.gov/10396320
https://pubmed.ncbi.nlm.nih.gov/10396320
Autor:
N, Mizobuchi, I, Takahashi, S, Yorimitsu, T, Horimi, K, Hamada, M, Matsuoka, H, Sonobe, M, Hiroi, I, Kubonishi
Publikováno v:
Acta medica Okayama. 53(2)
A new myeloid cell line, MTT-95, was established from the bone marrow of a patient with acute myelogenous leukemia (AML, M7). MTT-95 cells differentiate into mature basophilic cells in culture medium with no chemical component or cytokine. Surface ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a6e7302727bc1b65b40b602211db32a
https://pubmed.ncbi.nlm.nih.gov/10358725
https://pubmed.ncbi.nlm.nih.gov/10358725
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 25(10)
The patient was diagnosed to have gastric cancer (T3 N3 M0 P3, Stage IV b). We conducted LcFP therapy. CDDP, 7 mg/m2/day, day 1-5 i.v. drip for 2 hours, and 5-FU, 170 mg/m2/day, day 1-7, i.v. continuously for 24 hours. After 3 courses (one course: 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bccd9c05c036153d98708e0ef2b32880
https://pubmed.ncbi.nlm.nih.gov/9725054
https://pubmed.ncbi.nlm.nih.gov/9725054
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 25(6)
A study was conducted on weekly infusion of high-dose 5-FU through the hepatic artery for liver metastases from colorectal cancer. In the evaluation of 38 cases, no CR and 16 PR were to control the extrahepatic metastases is a subject for forthcoming
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0750a759e2e18edabb576a2c1740ead0
https://pubmed.ncbi.nlm.nih.gov/9617329
https://pubmed.ncbi.nlm.nih.gov/9617329